InsidersTradesSigma
Follow the Abeona Therapeutics INC. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Abeona Therapeutics INC. has published 209 insider filings. Market capitalisation: €334.5m. The latest transaction was reported on 1 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: O'Malley Brendan M.. The full history is openly available.
209
Insider Decl.
n/a
Thresholds
€368,807
12 ops.
Buy Volume
€4m
78 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Abeona Therapeutics INC. Strong Buy (bullish), based on 7 analysts. Average price target: US$18.86.
64Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,780 of 29,063 companies
58.0
score / 100
Value66
Quality50
FCF yld-25%
Earn yld21%
EV/EBITDA4.6x
ROE-43%
Gross mgn41%
Net mgn·
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 September 2026
Declarations209 total
15,000 shares@ US$5.8644Common StockSEC144:0001972481-26-000270
15,000 shares@ US$5.86440.026% mcap9.2% of flowCommon StockSEC:0001493152-26-041068:0
1,478 shares@ US$6.530.0026% mcap0.7% of flowCommon StockSEC:0001493152-26-034246:0
12,606 shares@ US$6.96370.022% mcap50.0% of flowCommon StockSEC144:0001972481-26-000231
67,971 shares@ US$6.96370.12% mcap18.6% of flowCommon StockSEC144:0001972481-26-000232
12,050 shares@ US$6.96370.021% mcap13.9% of flowCommon StockSEC144:0001972481-26-000229
24,880 shares@ US$6.96370.043% mcap21.2% of flowCommon StockSEC144:0001972481-26-000230
67,971 shares@ US$6.96370.12% mcap28.4% of flowCommon StockSEC:0001493152-26-032744:0
24,880 shares@ US$6.96370.043% mcap34.8% of flowCommon StockSEC:0001493152-26-032746:0
12,606 shares@ US$6.96370.022% mcap100.0% of flowCommon StockSEC:0001493152-26-032740:0
12,050 shares@ US$6.96370.021% mcap20.0% of flowCommon StockSEC:0001493152-26-032742:0
102,180 shares@ US$6.2710.16% mcap55.6% of flowCommon StockSEC144:0001972481-26-000224
11,000 sharesCommon StockSEC:0001493152-26-031906:0
222 sharesCommon StockSEC:0001493152-26-029092:0
18,160 shares@ US$5.71010.026% mcap7.6% of flowCommon StockSEC144:0001972481-26-000201
18,160 sharesCommon StockSEC:0001493152-26-028777:0
25,646 shares@ US$5.39220.034% mcap10.2% of flowCommon StockSEC144:0001972481-26-000188
13,421 sharesCommon StockSEC:0001493152-26-028022:1
4,826 sharesCommon StockSEC:0001493152-26-028019:0
6,305 sharesCommon StockSEC:0001493152-26-028019:1
24,428 sharesCommon StockSEC:0001493152-26-028020:0
31,916 sharesCommon StockSEC:0001493152-26-028020:1
4,170 sharesCommon StockSEC:0001493152-26-028021:0
5,450 sharesCommon StockSEC:0001493152-26-028021:1
10,271 sharesCommon StockSEC:0001493152-26-028022:0
25 of 209 declarations
关于 Abeona Therapeutics INC.
Abeona Therapeutics Inc. (ABEO) 是一家总部位于美国的商业阶段生物制药公司，在美国纳斯达克上市，专注于针对未满足医疗需求严重的疾病的细胞和基因疗法。公司总部位于俄亥俄州克利夫兰，并在当地运营一个集成的 cGMP 细胞和基因疗法生产设施，支持开发和商业供应。Abeona 的历史可追溯到 1974 年，当时它注册为 Chemex Corporation；后来在 2015 年更名为 Abeona Therapeutics Inc.，重新定位为罕见病和先进疗法开发。（[abeonatherapeutics.com](https://www.abeonatherapeutics.com/?utm_source=openai)） Abeona 最重要的现有资产是 ZEVASKYN® (prademagene zamikeracel)，这是一种细胞基因疗法，已于 2025 年 4 月获得美国 FDA 批准，用于治疗患有隐性营养不良性大疱性表皮松解症 (RDEB) 的成人和儿童患者的伤口。该公司将 ZEVASKYN 描述为美国市场上同类产品中首个也是唯一的自体细胞基因疗法，使 Abeona 在超专业罕见病领域占据了先发优势。商业执行依赖于美国合格治疗中心网络，该网络对于转诊、活检物流和治疗交付至关重要。（[investors.abeonatherapeutics.com](https://investors.abeonatherapeutics.com/press-releases/detail/303/u-s-fda-approves-zevaskyn-prademagene-zamikeracel?utm_source=openai)） 除了 ZEVASKYN，Abeona 继续投资于旨在将其平台扩展到肿瘤学和其他高价值领域的管线。其主要开发资产是 ABO-701，一种靶向 PSMA 的合成免疫受体 T 细胞疗法，正在开发用于晚期前列腺癌。该公司还强调 SIR 技术和病毒载体能力作为其更广泛研究平台的一部分，其战略目标是解决传统 CAR-T 方法在实体瘤中遇到的一些局限性。尽管这些项目仍处于早期阶段，但它们表明 Abeona 并未将自己定位为一家单一产品公司。（[abeonatherapeutics.com](https://www.abeonatherapeutics.com/pipeline-and-science/?utm_source=openai)） 从竞争角度来看，Abeona 在一个利基市场中运营，其中科学差异化、监管地位和生产控制比单纯的规模更重要。其潜在优势来自于结合了已获批准的疗法、内部生产能力和不断扩大的治疗中心网络。主要风险仍然是执行方面的：扩大 ZEVASKYN 的商业应用、保持生产质量和吞吐量，以及为正在进行的管线开发提供资金。2026 年最新的公司更新强调建立商业势头、扩大治疗活动和推进管线，这表明该公司已经超越了纯粹的研发阶段，但仍处于扩大新的罕见病特许经营权的早期阶段。（[nasdaq.com](https://www.nasdaq.com/press-release/abeona-therapeuticsr-reports-full-year-2025-financial-results-and-corporate-updates?utm_source=openai)）
